Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 1.00 |
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 20/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 0.78 |
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | HTR1E | P28566 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076496 | 0.90 | HTR2A (0.82) | HTR2AHTR2CHTR2BHTR7HTR1D | |
| SCHEMBL1476473 | 0.88 | HTR2A (0.81) | HTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL1475929 | 0.88 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL12844188 | 0.88 | HTR2A (0.78) | HTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL1476340 | 0.88 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR7HTR6 | |
| SCHEMBL14694235 | 0.88 | HTR2A (0.78) | HTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL1475754 | 0.87 | HTR2C (1.00) | HTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL1476518 | 0.87 | HTR2A (0.77) | HTR2AHTR2CHTR2BHTR7HTR1D | |
| SCHEMBL1475390 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR2BHTR7 | |
| SCHEMBL1476155 | 0.85 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | claimed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | claimed |
| EP-2016064-B1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-03 | — | — | EP | claimed |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | BONAVENTURE PASCAL | 2009-11-05 | — | — | US | claimed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | claimed |
| EP-2052251-A1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-29 | — | — | EP | claimed |
| EP-2016064-A2 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2009-01-21 | — | — | EP | claimed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | claimed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | claimed |
| WO-2008013556-A1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-01-31 | — | — | WO | claimed |
| WO-2007131153-A2 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070260057-A1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | claimed |
| JP-2007505908-A | — | — | 2007-03-15 | — | — | JP | claimed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | claimed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | claimed |
| EP-2052251-B1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-8883808-B2 | Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | HTR2A 9/4885HTR2C 5/4885HTR2B 13/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2A 9/4885HTR2C 5/4885HTR2B 13/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2A 9/4885HTR2C 5/4885HTR2B 13/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2A 9/4885HTR2C 5/4885HTR2B 13/4885 |
| US-20070260057-A1 | METHODS FOR THE PREPARATION OF PYRAZOLE-CONTAINING COMPOUNDS | HTR3C, HTR3A, HTR3B | HTR2A 16/4885HTR2C 8/4885HTR2B 14/4885 |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | HTR7, HTR1A, HTR6 | HTR2A 10/4885HTR2C 9/4885HTR2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.